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Alzheimer’s Disease (AD) is the most common Neurodegenerative Disease (ND), primarily characterised by neuroinﬂammation,
neuronal plaques of β-amyloid (Aβ), and neuroﬁbrillary tangles of hyperphosphorylated tau. α-Synuclein (α-syn) and its
heteroaggregates with Aβ and tau have been recently included among the neuropathological elements of NDs. These
pathological traits are not restricted to the brain, but they reach peripheral ﬂuids as well. In this sense, Red Blood Cells (RBCs)
are emerging as a good model to investigate the biochemical alterations of aging and NDs. Herein, the levels of homo- and
heteroaggregates of ND-related proteins were analysed at diﬀerent stages of disease progression. In particular, a validated animal
model of AD, the SAMP8 (Senescence-Accelerated Mouse-Prone) and its control strain SAMR1 (Senescence-Accelerated
Mouse-Resistant) were used in parallel experiments. The levels of the aforementioned proteins and of the inﬂammatory marker
interleukin-1β (IL-1β) were examined in both brain and RBCs of SAMP8 and SAMR1 at 6 and 8 months. Brain Aβ, tau, and
phospho-tau (p-tau) were higher in SAMP8 mice than in control mice and increased with AD progression. Similar
accumulation kinetics were found in RBCs, even if slower. By contrast, α-syn and its heterocomplexes (α-syn-Aβ and α-syn-tau)
displayed diﬀerent accumulation kinetics between brain tissue and RBCs. Both brain and peripheral IL-1β levels were higher in
SAMP8 mice, but increased sooner in RBCs, suggesting that inﬂammation might initiate at a peripheral level before aﬀecting the
brain. In conclusion, these results conﬁrm RBCs as a valuable model for monitoring neurodegeneration, suggesting peripheral
Aβ, tau, and p-tau as potential early biomarkers of AD.
1. Introduction
Alzheimer’s Disease (AD) is the most common form of Neu-
rodegenerative Disease (ND) and the leading cause of
dementia in the elderly population. The molecular hallmarks
associated with AD are primarily represented by misfolding
and brain deposition of β-amyloid protein 1-42 (Aβ), which
generates the amyloid plaques, and by neuroﬁbrillary tangles
(NTs) of hyperphosphorylated tau protein. According to the
“amyloid hypothesis,” Aβ promotes a glycogen synthase
kinase-mediated tau phosphorylation, resulting in amyloid
plaques and NTs, which damage the blood-brain barrier
and produce neuronal apoptosis, inﬂammation, and oxida-
tive stress [1]. In particular, it has been suggested that neuro-
inﬂammation in AD, particularly at its earlier stages, reﬂects
a vicious cycle of microglial activation, release of proinﬂam-
matory factors, and neuronal damage [2, 3].
At present, a mixed pattern of protein aggregates in AD
and other NDs has been identiﬁed [4, 5]. For instance,
besides amyloid plaques and NTs, the disease has been
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associated with intracellular accumulation of α-synuclein (α-
syn) [6], which represents the major component of Lewy
bodies and Lewy neuritis, and may play a role in amyloid
aggregation in senile plaques [7]. Interestingly, α-syn has
been shown to physically interact with tau [8, 9] or Aβ [8]
giving rise to the formation of hybrid proteins (“heteroaggre-
gates”) in brains of patients aﬀected by NDs [4, 5, 10].
Brain amyloid accumulation and aggregation have been
shown to kick oﬀ even decades before the onset of clinical
disease symptoms, and to reach the biological compartments.
In this context, cerebrospinal ﬂuid (CSF) has proven the
most explored medium, as it is deemed to reproduce brain
pathological processes [5, 11]. Consistently, AD diagnosis is
nowadays based on the identiﬁcation of misfolded-
aggregated proteins in the brain (where amyloid plaques
are visualised through imaging techniques) and CSF [12,
13]. However, considering the disadvantages that limit the
clinical use of CSF, several eﬀorts have been devoted to
explore ﬂuids other than CSF as a source of neurodegenera-
tion biomarkers. In this respect, it has been suggested that
pathological alterations of blood proteins reﬂect the changes
in CSF due to the simple diﬀusion or barrier impairment that
characterises neurodegeneration [11, 14].
Red Blood Cells (RBCs) are emerging as a good model
to investigate the biochemical alterations related to aging
and neurodegeneration, including oxidative stress and
inﬂammation [15, 16]. Indeed, RBCs are highly susceptible
to oxidative damage, due to the high concentration of oxy-
gen and haemoglobin [17, 18]. Moreover, recent ﬁndings
have shown an accumulation of ND-related proteins in
these cells and its relationship with NDs [11, 19–21]. In
particular, the presence of misfolded proteins (α-syn, Aβ,
and tau) and their aggregates (α-syn-Aβ and α-syn-tau)
has been recently proved in RBCs from healthy subjects
and patients with NDs [5, 10, 11, 22]. At present, putative
correlation between the accumulation of the aforemen-
tioned proteins in the brain and RBCs and inﬂammation
has never been investigated.
To this end, we used here an animal model of AD,
SAMP8 (Senescence-Accelerated Mouse-Prone), which is
characterised by an early beginning of irreversible and severe
learning and memory deﬁcits. At a molecular level, this ani-
mal model displays an increase in Aβ proteins in hippocam-
pal granules, hyperphosphorylation of tau protein, increase
in α-synuclein, and increase in oxidative damage [23].
SAMR1 (Senescence-Accelerated Mouse-Resistant), which
does not develop the disease [23], was used as control.
Herein, misfolded proteins were quantiﬁed in both the
brain and RBCs of SAMP8 and SAMR1 mice, in order to
establish a correlation between brain and peripheral ﬂuids,
as well as to ascertain the putative use of misfolded proteins
in RBCs as AD biomarkers. Finally, to establish the link
between brain/peripheral inﬂammation and accumulation
of ND-related proteins, interleukin-1β (IL-1β) was quanti-
ﬁed as one representative marker [14]. Indeed, neuroinﬂam-
matory cytokines, including IL-1β, have been involved in the
formation of AD neuritic plaques [24–26] and were found in
higher quantities in AD with respect to controls in both
humans and animals [27–29].
2. Materials and Methods
2.1. Animals. SAMP8 mice (2 months old, 20-25 g body
weight), employed as a spontaneous genetic model of AD
[30], and their control strain SAMR1 (2 months old, 20-25
g body weight) were purchased from Envigo SRL (San Pietro
al Natisone UD, Italy).
Animal care and handling were in accordance with the
provisions of the European Community Council Directive
210-63-EU, recognised and adopted by the Italian Govern-
ment. The experiments were approved by the Ethical Com-
mittee for Animal Experimentation of the University of
Pisa and by the Italian Ministry of Health (authorization
no. 198-2016-PR). One day after the end of cognitive tests
(see the following discussion), the animals were euthanized
by cervical dislocation and the cerebral cortex was carefully
isolated by microscopic forceps. Blood samples were col-
lected by cardiac puncture.
In the acquisition training, animals are subjected to ses-
sions of four trials every day for 2 days. In the hidden-
platform training, performed by submerging the platform
1.5 cm below the surface of the water, animals are subjected
to sessions of four trials every day for 5 days. Finally, in the
probe trial on the eighth day, the platform is removed and
the number of target crossings, number of entries into the
target quadrant, and the time spent in the target quadrant
are assessed as measures for 60 s.
2.2. Evaluation of Cognitive Functions: Morris Water Maze
Test and Behavioural Test. The behavioural test consists of
visible-platform acquisition training, hidden-platform train-
ing, and probe trial (Figure 1). The platform was in the same
location for both visible-platform training and hidden-
platform training. In the acquisition training, the escape
latency was assessed for each animal (time required to reach
the platform). Mice were placed on the platform for 10 s
before being released into the water. Mice were allowed to
swim and ﬁnd the visible platform within 60 s. Each animal
was subjected to sessions of four trials every day for 2 days.
After the daily trial, mice were returned to their home cages
for resting. In the hidden-platform training, performed by
submerging the platform 1.5 cm below the surface of the
water, escape latency was evaluated over the next 5 days
(Figure 1). Each animal was subjected to sessions of four tri-
als every day. Finally, on the eighth day, the platform was
removed from the tank for the probe trial (Figure 1). The
number of target crossings, number of entries into the target
quadrant, the time spent in the target quadrant where the
platform was placed, the swimming speed, swim distance,
and swim distance in the target quadrant were assessed as
measures for 60 s. Data are expressed as raw values, while
the data regarding the time spent in the target quadrant are
expressed as the percent time spent in the quadrant with
the platform in comparison to each of the other quadrants.
2.3. Collection of Brain Tissues and RBCs. Brains were dis-
sected from mice. The samples were suspended in
phosphate-buﬀered saline (PBS) and then sonicated. The
blood was sampled from mice, and it was preserved into an
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EDTA tube. A centrifugation at 200 × g at 4°C for 10 min was
required to isolate RBCs from plasma. The RBC pellet was
suspended in 3 ml of PBS and subjected to centrifugation at
1000 × g for 10 min and washed thrice with PBS. Finally,
RBCs were centrifuged at 1500 × g for 10 min and frozen at
-20°C until use.
2.4. Coimmunoprecipitation-Western Blotting. RBC (1 mg)
and brain (30 μg) samples were lysed in RIPA buﬀer and later
resolved by SDS-PAGE (8.5%) to assess the expression of Aβ,
α-syn, and tau. Samples were transferred to PVDF mem-
branes and probed overnight at 4°C with primary antibodies
to Aβ (β-amyloid H-43, sc-9129, Santa Cruz Biotechnology
Inc.), α-syn (α-β synuclein N-19, sc-7012, Santa Cruz Bio-
technology Inc.), or tau (H-150, sc-5587, Santa Cruz Biotech-
nology Inc.) [11, 22]. Then, the primary antibodies were
revealed through peroxidase-conjugated secondary antibod-
ies and a chemiluminescent substrate (ECL, PerkinElmer).
A coimmunoprecipitation assay was used to prove the
presence of α-syn heterocomplexes with Aβ or tau [11, 22].
Brieﬂy, lysates (1 mg) recovered from RBCs or the brain were
suspended in RIPA buﬀer; they were probed with an anti-α-
syn antibody (5 μg sample), maintained under constant rota-
tion overnight, and successively immunoprecipitated with
protein A-Sepharose. The immunocomplexes were sus-
pended in Laemmli solution following an extensive washing;
thereafter, the immunocomplexes were determined by SDS-
PAGE and probed overnight with primary antibodies to α-
syn (input), Aβ, or tau as described previously [11, 22].
2.5. Preparation of Aged Solutions of α-Syn and of the α-Syn-
Biotinylated Antibody. The incubation of recombinant α-syn
took place in paraﬁlm-sealed tubes at 37°C for 4 days in
an Eppendorf ThermoMixer under continuous mixing
(1000 rpm) [31]. The α-syn-biotinylated antibody was pre-
pared through a reaction among Sulfo-NHS-LC-Biotin
(Pierce, Rockford, IL, USA) (200 mg) and the 211 mouse
monoclonal antibody (mAb) (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) [32]. To remove excess
uncoupled biotin, the mixture was desalted on Bio-Spin-6
Columns (Bio-Rad, UK) [11, 22].
2.6. Immunoassay Methods. The presence and quantiﬁcation
of total Aβ, tau, and α-syn and its heterocomplexes (α-syn-
Aβ and α-syn-tau) in RBCs and in brain tissues were assessed
by a “homemade” sandwich enzyme-linked immunosorbent
assay (ELISA) system [11, 33, 34]. The plate was precoated
overnight with 60 μl-well of a speciﬁc antibody directed to
the protein in analysis. Following an extensive washing with
PBS-T (PBS, containing 0.01% Tween 20), BSA 1% (200 μl-
well) was added to block nonspeciﬁc sites and the plate was
incubated. After additional washes with PBS-T, RBCs and
brain tissues were added to each well (100 μl-well) and incu-
bated. Following an extensive washing, an antibody (75 μl-
well) directed to a speciﬁc amino-acidic sequence of the pro-
tein was employed for capturing, followed by an incubation.
For antigen detection, an HRP antibody (100 μl-well) was
used and it was incubated [11]. The wells were then washed
with PBS-T before the addition of 100 μl-well of 3,3′,5,5′
-tetramethylbenzidine (TMB) (Thermo Fisher Scientiﬁc).
The absorbance was evaluated at 450 nm after the addition
of the Stop Solution (0.4 N HCl, 100 μl-well). All measure-
ments were performed in duplicate to reduce interassay var-
iability. The standard curve for the ELISA assay was
constructed using a recombinant human protein solution at
diﬀerent concentrations diluted in PBS [11, 22, 34]. The con-
centration of ND-related proteins in the brain and RBCs was
expressed as the nanogram or picogram of protein and nor-
malised to the quantity of total proteins present in the ana-
lysed samples.
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Figure 1: (a) Diagram showing the timing of cognitive impairment and AD progression in SAMP8 mice. (b) Diagram showing the diﬀerent
phases of the behavioural test.
3Oxidative Medicine and Cellular Longevity
2.6.1. Detection of Total α-Synuclein. The plate was coated
with full-length polyclonal antibody to α-syn (sc-10717,
Santa Cruz Biotechnology Inc.) overnight at 4°C. After the
incubation with BSA 1% and three washes with PBS-T, RBCs
(0.1 mg-100 μl) and brain tissues (10 μg-100 μl) were added
to each well and incubated at 25°C for 2 h. Then, mouse
monoclonal antibody to α-syn (sc-12767, Santa Cruz Bio-
technology Inc.) was employed and incubated at 37°C for 2
h. An anti-mouse-HRP antibody was used, and it was incu-
bated at 37°C for 1.5 h [11, 21, 22, 35].
2.6.2. Detection of Total Aβ.A precoating with a speciﬁc anti-
body to Aβ (sc-9129, Santa Cruz Biotechnology Inc.) was
prepared (60 μl-well) and maintained overnight at 4°C.
BSA 1% was added and the plate was incubated for 2 h at
37°C. RBCs (0.05 mg-100 μl) and brain tissues (0.25 μg-100
μl) were added to each well and incubated at 25°C for 1 h.
Samples were probed with polyclonal antibody to Aβ (sc-
5399, Santa Cruz Biotechnology Inc.) (75 μl-well) for 1.5 h
at 25°C. For antigen detection, a donkey anti-goat-HRP anti-
body was incubated at 37°C for 1 h [11, 32, 36].
2.6.3. Detection of Total Tau. The plate was precoated with a
speciﬁc antibody to tau (sc-32274, Santa Cruz Biotechnology
Inc.) and left overnight at 4°C. BSA 1% was added and the
plate was incubated for 1 h at 37°C. RBCs (0.4 mg-100 μl)
and brain tissues (2 μg-100 μl) in each well were incubated
at 25°C for 2 h. Samples were probed with polyclonal anti-
body to tau (sc-5587, Santa Cruz Biotechnology Inc.) and
incubated at 37°C for 2 h. A goat anti-rabbit-HRP antibody
(Invitrogen) was incubated for 1.5 h [11, 32, 36].
2.6.4. Detection of Phospho-Tau. The plate was precoated
with a speciﬁc antibody to tau (sc-32274, Santa Cruz Biotech-
nology Inc.) and left overnight at 4°C. BSA 1% (200 μl-well)
was added, and the plate was incubated for 2 h at 37°C. RBCs
(0.2 mg-100 μl) and brain tissues (1 μg-100 μl) in each well
were incubated at 25°C for 2 h. Samples were probed with
polyclonal antibody to tau (70R-32555, Fitzgerald Industries
International) and incubated at 37°C for 1.5 h. For antigen
detection, goat anti-rabbit-HRP antibody (Invitrogen) was
incubated for 1.5 h [11, 32].
2.6.5. Immunoassay Detection of α-Syn-Tau
Heterocomplexes. The ELISA plate was coated with α-β-syn
N-19 antibody (sc-7012, Santa Cruz Biotechnology Inc.)
overnight at room temperature. RBCs (400 μg-100 μl) and
brain tissues (1 μg-100 μl) were added to each well and incu-
bated at 25°C for 2 h. BSA 1% was added to each well for 20
min at 37°C. Rabbit polyclonal anti-tau H-150 antibody (sc-
5587, Santa Cruz Biotechnology Inc., 37°C for 2 h) was
employed for capturing. A goat anti-rabbit-HRP antibody
was used at 37°C for 1.5 h [11]. The concentration of α-
syn-tau interaction in the samples was quantiﬁed accord-
ing to a standard curve [11], which was constituted using
a solution of recombinant human α-syn and recombinant
human tau at diﬀerent concentrations in SDS 2 mM.
The solution was prepared by incubating 1 mg of each
protein, diluted in 2 mM SDS, in paraﬁlm-sealed tubes
at 37°C for 1 h in an Eppendorf ThermoMixer with con-
tinuous mixing (500 rpm) [11, 22].
2.6.6. Immunoassay Detection of α-Syn-Aβ Heterocomplexes.
The ELISA plate was coated with β-amyloid H-43 antibody
(sc-9129, Santa Cruz Biotechnology Inc.) overnight at room
temperature. RBCs (0.2 mg-100 μl) and brain tissues (1 μg-
100 μl) were added to each well and incubated at 25°C for 2
h. BSA 1% was incubated for 20 minutes at 37°C. A mouse
monoclonal anti-α-synuclein 211 antibody (sc-12767, Santa
Cruz Biotechnology Inc.) was employed for capturing and
was incubated at 37°C for 2 h. Goat anti-mouse-HRP anti-
body was incubated at 37°C for 1.5 h [11]. The concentration
of α-syn-Aβ interaction in the samples was quantiﬁed
according to a standard curve [11], which was constituted
using a solution of recombinant human α-syn and recombi-
nant human Aβ at diﬀerent concentrations in SDS 2 mM.
The solution was prepared by incubating 1 mg of each pro-
tein, diluted in 2 mM SDS, in paraﬁlm-sealed tubes at 37°C
for 16 h in an Eppendorf ThermoMixer with continuous
mixing (500 rpm) [11, 37].
2.7. Evaluation of IL-1β Levels in Brain Tissues and in RBCs.
IL-1β levels in the cerebral cortex and RBCs were measured
by a commercial enzyme-linked immunosorbent assay kit
(Abcam, Cambridge, UK), as previously described. Brieﬂy,
20 mg of cerebral cortex, stored previously at -80°C, were
homogenised in 400 μl of PBS, pH 7.2, at 4°C and centrifuged
at 10000 × g for 5 min. Aliquots (50 μl) of the supernatants
were then used for the assay. In parallel, 0.2 mg-50 μl of
RBCs, homogenised in PBS, were used for the assay. IL-1β
levels were expressed as picogram per milligram of total pro-
teins present in the analysed samples.
2.8. Statistical Analysis. The results are presented as the
mean ± S E M unless otherwise stated. The signiﬁcance of
diﬀerences was evaluated by a two-way analysis of variance
followed by post hoc analysis with the Fisher LSD test or a
one-way analysis of variance followed by post hoc analysis
with the Student-Newman-Keuls test where appropriate. P
values <0.05 were deemed signiﬁcantly diﬀerent. All statisti-
cal procedures were performed by commercial software
(GraphPad Prism, version 7.0; GraphPad Software Inc., San
Diego, CA).
3. Results
3.1. Evaluation of Cognitive Functions (Morris Water Maze
Test). As a ﬁrst step, mice cognitive functions, i.e., spatial
learning and memory ability, were evaluated by the Morris
water maze test. SAMR1 mice rapidly learned the location
of the platform (Figure 2(a)). SAMP8 mice at 4, 6, and 8
months displayed a signiﬁcant increase in escape latency
time at every test day compared with SAMR1 mice
(Figure 2(a)).
These ﬁndings are in line with other studies showing that
SAMP8 mice displayed a signiﬁcant increase in escape
latency time since the ﬁrst day of training as compared with
SAMR1 mice, while no signiﬁcant diﬀerence was observed
among training days [38, 39].
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During the probe trial, the number of target crossings as
well as the entries into the target quadrant were signiﬁcantly
decreased in SAMP8 mice at 6 and 8 months, compared with
respective controls (SAMR1) and SAMP8 animals at 4
months (Figures 2(b) and 2(c)). The time spent within the
target quadrant was signiﬁcantly decreased in SAMP8 mice
at 8 months, compared with respective SAMR1 animals
and SAMP8 mice at 4 and 6 months (Figure 2(d)). Consider-
ing the swimming speed, the swim distance, and the swim
distance in the target quadrant, our results show that SAMP8
animals displayed a decrease in swimming speeds and dis-
tance traveled, as compared with age-matched SAMR1
(Figures 3(a)–3(c)). Of note, our results point out that
SAMP8 animals did not ﬂoat in the quadrant where the plat-
form was located, but they reached it slowly, thus exclud-
ing despair or depression signs. In addition, the number of
target crossings and the entries into the target quadrant
were signiﬁcantly decreased in SAMP8 mice starting from
6 months of age as compared with age-matched SAMR1,
while the time spent in the target quadrant decreased sig-
niﬁcantly in SAMP8 animals at 8 months of age. This dis-
crepancy could be ascribed to a learning and memory
deﬁcit in looking for the platform and to a decrease in
swimming speed, as well as to a reduced motivation to
escape from the water of SAMP8 mice not being in an
aversive situation [40].
Altogether, these data conﬁrm that SAMP8 mice develop
a deﬁcit in spatial learning and memory performance
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Figure 2: Cognitive performance of SAM. (a) Escape latency in SAMR1 and SAMP8 mice at 4, 6, and 8 months of age, during seven
consecutive days of Morris water maze test training. Cognitive performance of SAMR1 and SAMP8 mice at 4, 6, and 8 months of age,
during the probe trial session of the Morris water maze test; (b) number of target crossings; (c) entries into the target quadrant; (d) time
spent within the target quadrant. Data are expressed as mean ± S E M obtained from 8 animals. Diﬀerences among groups were evaluated
by two-way analysis of variance followed by post hoc analysis with the Fisher LSD test or a one-way analysis of variance followed by post
hoc analysis with the Student-Newman-Keuls test where appropriate. ∗P < 0 05 between the indicated subgroups.
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compared with control SAMR1mice. Moreover, such deﬁcits
become clearer as AD develops in SAMP8 mice.
3.2. Expression of α-Syn, Tau, and Aβ in Brain Tissues and
RBCs: Immunoblotting Analysis. The presence of AD-
related misfolded proteins (i.e., α-syn, tau, and Aβ) was
assessed by western blotting analysis in brain and RBC sam-
ples obtained from SAM mice. The quantitative comparison
between pathological and control animals was subsequently
performed by immunoenzymatic assays. Considering the
timing of ageing, the demonstrated cognitive impairment,
and the onset of the pathological processes, samples obtained
from 4-month animals were excluded from further investiga-
tions, focusing on the brain tissues and RBCs obtained from
animals at 6 and 8 months.
The anti-Aβ antibody recognised 5 and 15 kDa proteins
(Figure 4(a)) corresponding to Aβ monomeric and oligomer
forms, respectively [41], in both brain tissues and RBCs.
Bands with a molecular weight higher than 25 kDa
(Figure 4(a)) were especially revealed in brain tissues,
presumably indicating elevated oligomeric forms of the
protein [42].
In brain tissues, the anti-tau antibody revealed the char-
acteristic bands (Figure 4(b)) ranging from 55 to 74 kDa
[11, 43, 44]. Worth noting, a band lower than 50 kDa, which
was particularly evident in RBCs (Figure 4(b)), has been
related to truncated or cleaved forms of tau containing the
C-terminal region [11, 43, 44]. These data demonstrate that
the antibody is able to recognise both truncated and
uncleaved forms of the protein and that the triplet bands
do not refer to oligomeric tau.
Finally, the anti-α-syn antibody-labelled proteins of 15
kDa and 30 kDa proteins correspond to α-syn [43] in both
brain tissues and RBCs (Figure 4(d)).
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Figure 3: Cognitive performance of SAM. Cognitive performance of SAMR1 and SAMP8 mice at 4, 6, and 8 months of age, during the probe
trial session of the Morris water maze test: (a) swimming speed; (b) swim distance; (c) swim distance in the target quadrant. Data are
expressed as mean ± S E M obtained from 8 animals. Diﬀerences among groups were evaluated by two-way analysis of variance followed
by post hoc analysis with the Fisher LSD test or a one-way analysis of variance followed by post hoc analysis with the Student-Newman-
Keuls test where appropriate. ∗P < 0 05 between the indicated subgroups.
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3.3. Expression of α-Syn Heterocomplexes with Tau or Aβ
in Brain Tissues and RBCs of SAM Mice. A
coimmunoprecipitation-western blotting assay was employed
to explore the presence of α-syn heterocomplexes in brain and
RBC samples of SAM mice (Figure 5). To this purpose, lysates
obtained from brain tissues or RBCs were immunoprecipitated
using an anti-α-syn antibody and then immunoblotted with a
speciﬁc antibody for α-syn (i.e., input), tau, or anti-Aβ [11].
In α-syn immunoprecipitates (Figure 5(a)), two major bands
of 15 kDa and 30 kDa, corresponding to α-syn protein [11,
45], were noticed in both brain tissues and RBCs.
The Aβ immunoblotting on α-syn immunoprecipitates
obtained from brain tissues and RBCs produced two main
immunoreactive bands of 5 and 30 kDa (Figure 5(b)), mainly
associated to monomeric and oligomeric Aβ forms [11].
Moreover, probing α-syn immunoprecipitates with an anti-
tau antibody showed an immunoreactive band of 55 kDa,
ascribable to the tau protein (Figure 5(c)). Altogether, the
results demonstrated that α-syn forms heterocomplexes with
Aβ and tau in brain tissues and in RBCs of SAM mice, simi-
larly to previous data reported in human samples [5, 11, 22].
3.4. Concentrations of α-Syn, Tau, and Aβ in Brain Tissues
and RBCs of SAM Mice. Speciﬁc and quantitative immu-
noenzymatic assays were employed to measure α-syn, tau,
and Aβ levels in brain tissues and RBCs of SAMP8 mice at
diﬀerent stages of AD progression and their age-matched
SAMR1 controls. The values are set out in Table 1.
3.4.1. Aβ. The amount of Aβ in the brain did not change with
age either in SAMR1 or in SAMP8 (Figure 6(a)), although an
incremental trend was noticed. By contrast, SAMP8 animals
showed signiﬁcantly higher Aβ concentrations than age-
matched SAMR1 mice (6 months: P = 0 0193; 8 months:
P = 0 0104), consistent with previous data. These results con-
ﬁrm that Aβ accumulated early in the brain of AD animals.
As observed in the brain, the levels of Aβ in RBCs of
SAMR1 did not change with age (Figure 6(b)). By contrast,
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Figure 4: Detection of misfolded proteins in cell lysates of RBCs and brain tissues by western blot analysis. Cell lysates of RBCs and brain
tissues from SAMs were immunoblotted with antibodies to Aβ (a), tau (b), and α-syn (d). (c, e) GAPDH was used as a loading control for
Aβ and tau (c) or for α-syn (e) normalisation. A representative image for each protein is shown (n = 3).
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Aβ signiﬁcantly accumulated with age in RBCs from SAMP8
(P = 0 0270, Figure 6(b)). Moreover, SAMP8 animals at 8
months displayed signiﬁcantly higher Aβ RBC levels than
the age-matched SAMR1 (P = 0 0279), consistent with the
data obtained in the brain. By contrast, comparable levels were
noticed in SAMP8 and SAMR1 at 6 months (P = 0 3029,
Figure 6(b)). These data suggest that Aβ accumulated in RBCs
with AD progression, albeit with a slower accumulation kinet-
ics than that observed in the brain.
3.4.2. Tau. Brain levels of total tau (Figure 6(c)) were proven
to increase signiﬁcantly with age either in SAMR1
(P = 0 0293) or in SAMP8 mice (P = 0 0095). Moreover,
SAMP8 animals at 8 months displayed signiﬁcantly higher
brain concentrations of total tau compared to their age-
matched controls (P = 0 0350). These data conﬁrm that tau
accumulated in the brain along with AD progression in the
SAM experimental model.
Tau concentrations in RBCs increased with age in
SAMP8 only (P = 0 0019; SAMR1: P = 0 7430, Figure 6(d)).
Consistent with the data obtained in the brain, total tau sig-
niﬁcantly accumulated in RBCs of SAMP8 mice at 8 months
compared to control mice (P = 0 00019, Figure 6(d)). These
results suggest that tau accumulation in RBCs in pathological
mice may reﬂect the increase of this protein in the brain.
3.4.3. Phospho-Tau. The levels of p-tau in the brain
(Figure 6(e)) did not diﬀer with mice ages, either in SAMP8
or in SAMR1 (P = 0 4140 and P = 0 5737, respectively,
Figure 6(e)). By contrast, pathological mice displayed signif-
icantly higher levels of brain p-tau compared to the age-
matched controls, either at 6 months or at 8 months
(P = 0 0485 and P = 0 0010, respectively, Figure 6(e)). These
data conﬁrm that tau is hyperphosphorylated in the brain
of the AD animal model.
Interestingly, an age-dependent p-tau accumulation
was observed in RBCs, both in control (P = 0 0011,
Figure 6(f)) and SAMP8 mice (P = 0 0015, Figure 6(f)).
Nevertheless, no signiﬁcant changes in p-tau levels in
RBCs were observed comparing SAMP8 and SAMR1 (6
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Figure 5: Detection of α-syn heterocomplexes with tau and Aβ in RBCs and brain samples. From SAMs, cell lysates of RBCs and brain tissues
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Table 1: Concentrations of Aβ, α-syn, tau, p-tau, α-syn-Aβ, and α-syn-tau in brain tissues and RBCs of SAMP8 and SAMR1 at diﬀerent ages.
Brain Aβ (ng/μg) α-Syn (ng/μg) Tau (ng/μg) p-Tau (pg/μg) α-Syn-Aβ (ng/μg) α-Syn-tau (ng/μg)
SAMR1 6 m 7 63 ± 3 06 6 22 ± 4 59 7 51 ± 3 10 158 ± 92 2 1 35 ± 1 36 2 08 ± 1 58
SAMP8 6 m 13 5 ± 4 75∗ 15 5 ± 7 73∗ 7 28 ± 2 77 327 ± 118∗ 2 70 ± 1 77 8 74 ± 3 12∗∗
SAMR1 8 m 8 81 ± 3 72 8 54 ± 5 94 13 0 ± 3 6# 123 ± 105 2 81 ± 1 68 1 54 ± 1 04
SAMP8 8 m 15 5 ± 4 8∗ 0 69 ± 0 42∗∗## 22 1 ± 6 0∗## 397 ± 152∗∗∗ 0 53 ± 0 50∗# 1 17 ± 1 49###
RBCs Aβ (ng/mg) α-Syn (ng/mg) Tau (ng/mg) p-Tau (ng/mg) α-Syn-Aβ (ng/mg) α-Syn-tau (ng/mg)
SAMR1 6 m 147 ± 48 1 37 5 ± 25 2 14 7 ± 1 59 0 36 ± 0 09 19 7 ± 13 6 3 56 ± 2 77
SAMP8 6 m 121 ± 68 6 279 ± 242∗∗∗ 12 1 ± 6 95 0 36 ± 0 09 39 9 ± 23 8∗ 4 78 ± 6 04
SAMR1 8 m 123 ± 13 5 39 1 ± 47 4 14 0 ± 6 38 0 92 ± 0 74## 40 7 ± 50 7# 3 70 ± 3 57
SAMP8 8 m 213 ± 120∗# 204 ± 186∗∗ 34 4 ± 23 9∗# 1 21 ± 1 33## 103 ± 99 4# 8 67 ± 5 45∗##
Values are expressed as mean ± SD. Diﬀerences among the groups were evaluated by a nonparametric analysis (Kruskal-Wallis). ∗P < 0 05, ∗∗P < 0 01, and
∗∗∗P < 0 001 indicate signiﬁcant diﬀerences of SAMR1 versus the age-matched SAMP8. #P < 0 05, ##P < 0 01, and ###P < 0 001 indicate signiﬁcant
diﬀerences between SAMR1 6 m and SAMR1 8 m or between SAMP8 6 m and SAMP8 8 m.
8 Oxidative Medicine and Cellular Longevity
months: P = 0 6965; 8 months: P = 0 09401, Figure 6(f)).
These results suggest that phosphorylated tau accumulated
in RBCs both under physiological ageing and AD
progression.
3.4.4. α-Syn. The brain concentrations of total α-syn signiﬁ-
cantly decreased with animals’ age in SAMP8 (P = 0 0095,
Figure 7(a)), but not in control animals (P = 0 5622,
Figure 7(a)), suggesting that total α-syn decreases as the
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Figure 6: Quantitative assay of misfolded protein Aβ, tau, and p-tau in RBCs and brain tissues. The levels of Aβ, tau, and p-tau in brain
tissues (a, c, and e) and RBCs (b, d, and f) from SAMP8 and SAMR1 mice at 6 and 8 months were assessed by speciﬁc immunoenzymatic
assays. Diﬀerences among groups were evaluated by one-way ANOVA. P values were adjusted with Sidak’s multiple comparison test: ∗P
< 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001 between the indicated subgroups.
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disease progresses. Consistent with these data, SAMP8 mice
at 8 months presented signiﬁcantly lower brain concentra-
tions of total α-syn compared to age-matched controls
(P = 0 0022, Figure 7(a)). Surprisingly, the opposite condi-
tion was found when comparing animals at 6 months
(P = 0 0240, Figure 7(a)).
Total α-syn in RBCs did not show signiﬁcant variations
with age (SAMR1: P = 0 2643, Figure 7(b)) or AD progres-
sion (SAMP8: P = 0 8968, Figure 7(b)). Diﬀerently from the
brain, RBCs from SAMP8 animals showed signiﬁcantly
higher total α-syn concentrations compared to the age-
matched controls (6 months: P < 0 0001; 8 months: P =
0 0097, Figure 7(b)). Globally, these data suggest a diﬀerent
kinetics of α-syn in peripheral ﬂuids compared to the brain.
3.5. Concentrations of α-Syn Heterocomplexes in Brain
Tissues and RBCs. α-Syn heterocomplexes with Aβ or tau
were measured both in brain tissues and RBCs through a
“homemade” immunoenzymatic assay [11, 22].
3.5.1. α-Syn-Aβ. The levels of α-syn-Aβ in SAMP brains
(Figure 7(c)) showed an interesting trend depending on age-
ing and progression of the disease. Indeed, the brain concen-
trations decreased along with age-AD progression in SAMP8
mice (P = 0 0303, Figure 7(c)). Moreover, α-syn-Aβ levels in
the brain decreased in SAMP8 at 8 months compared to age-
matched controls (P = 0 0101, Figure 7(c)). These data sug-
gest that brain α-syn-Aβ levels may follow the accumulation
kinetics of total α-syn.
Surprisingly, α-syn-Aβ levels in RBCs increased with
age-AD progression in SAMR1 (P = 0 0017, Figure 7(d))
and SAMP8 mice (P = 0 0308). Moreover, such levels in
RBCs were higher in SAMP8 compared to age-matched con-
trols, even if a statistical signiﬁcance was reached at 6 months
only (6 months: P = 0 0168; 8 months. P = 0 1797,
Figure 7(d)). These data suggest that the α-syn-Aβ level in
RBCs has an opposite trend compared to that in the brain.
3.5.2. α-Syn-Tau. The levels of α-syn-tau heterocomplexes in
the brain decreased with the pathological progression in
SAMP8 mice (P = 0 0002, Figure 7(e)). Nevertheless, such
concentrations were signiﬁcantly elevated in SAMP8 com-
pared to SAMR1 at 6 months (P = 0 0012, Figure 7(e)).
Taken together, these data suggest that the α-syn-tau trend
in the brain reﬂects what is elicited by α-syn.
The levels of α-syn-tau heterocomplexes in RBCs did not
signiﬁcantly diﬀer in SAMR1 at diﬀerent ages (P = 1 000,
Figure 7(f)) or between SAMR1 and SAMP8 at 6 months
(P = 0 8907, Figure 7(f)). By contrast, α-syn-tau concentra-
tions increased in SAMP8 mice at 8 months compared to
the age-matched controls (P = 0 0155, Figure 7(f)) or to
SAMP8 at 6 months (P = 0 0025, Figure 7(f)). These data
suggest that the α-syn-tau level in RBCs has an opposite
trend compared to that in the brain.
3.6. Assessment of IL-1β Levels in Brain Tissues and RBCs. In
order to monitor the progress of inﬂammation in the animal
model of AD, IL-1β was chosen as a representative inﬂam-
matory factor [14] and measured in brain tissues of SAMP8
mice and in their age-matched SAMR1 controls.
In the cerebral cortex from SAMR1 mice at 6 and 8
months, IL-1β levels accounted for 1 3 ± 0 5 and 3 3 ± 0 4
pg −mg, respectively (Figure 8(a)), suggesting an increase
in interleukin levels with physiological ageing. At 6 months,
SAMP8 mice showed IL-1β levels of 1 8 ± 0 7 pg −mg in
the cerebral cortex (Figure 8(a)), which were comparable to
those detected in the respective age-matched control
(SAMR1) mice. By contrast, IL-1β levels in the cerebral cor-
tex from SAMP8 mice at 8 months were signiﬁcantly
increased (29 6 ± 5 4 pg −mg) compared to the age-
matched controls (SAMR1) and to SAMP8 mice at 6 months
(Figure 8(a)). These data suggest that brain IL-1β concentra-
tions increased in the AD animal model and that such an
increase became more prominent with age (i.e., with AD pro-
gression) in SAMP8 mice compared with aged SAMR1 mice.
In order to check whether brain inﬂammation was asso-
ciated with an enhancement in peripheral inﬂammatory fac-
tors, IL-1β concentration was monitored in RBCs, which are
able to produce cytokines, too [46]. The interleukin signiﬁ-
cantly accumulated with ageing (6 months vs. 8 months) in
RBCs of SAMR1 mice (Figure 8(b)). Surprisingly, an oppo-
site trend was observed in SAMP8 mice (Figure 8(b)), which
displayed the highest IL-1β concentrations at 6 months
(839 7 ± 398 1 pg −mg, Figure 8(b)). The IL-1β concentra-
tion in RBCs was signiﬁcantly higher in SAMP8 mice at 6
months compared to the age-matched control (i.e., SAMR1,
6 months, 384 4 ± 72 98 pg −mg); by contrast, comparable
values were obtained in SAMP8 and SAMR1 at 8 months
(538 8 ± 421 2 and 460 9 ± 42 12 pg −mg, Figure 8(b)).
Overall, these data show that the inﬂammatory cytokine is
released maximally in RBCs during the initial phases of AD
development. Moreover, the cytokine accumulation in RBCs
seems to follow a faster accumulation kinetics compared to
that elicited in the cerebral cortex.
4. Discussion
In the present study, the brain accumulation of
neurodegeneration-related proteins such as homo- and het-
eroaggregates was analysed and compared to the levels of
the same proteins in RBCs, using a validated animal model
of AD at diﬀerent stages of disease progression. Moreover,
the amounts of IL-1β, chosen as a marker of AD-associated
inﬂammation, were analysed both in brain tissues and RBCs.
The main conclusions of this work are as follows: (a) brain
Aβ, tau, and p-tau were elevated in SAMP8 mice compared
to control and increased with AD progression; similar,
although slower, accumulation kinetics were found in RBCs;
(b) α-syn and its heterocomplexes, α-syn-Aβ and α-syn-tau,
showed diﬀerent accumulation kinetics in brain tissues and
RBCs; and (c) both brain and peripheral IL-1β levels were
elevated in SAMP8 mice, but increased earlier in RBCs.
Overall, these results support RBCs as a valuable model to
monitor neurodegeneration, suggesting Aβ, tau, and p-tau
levels as suitable AD biomarkers in peripheral cells, both
for diagnosis and follow-up.
Recent ﬁndings have suggested that each ND is not asso-
ciated with the misfolding of a single speciﬁc protein, but
rather with a mixed pattern of proteinopathies [4, 5], which
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Figure 7: Quantitative assay of α-syn and misfolded protein’s heterocomplex in both RBCs and in brain tissues. Levels of α-syn, α-syn-Aβ,
and α-syn-tau in brain tissues (a, c, and e) and in RBCs (b, d, and f) from SAMP8 and SAMR1 mice at 6 and 8 months were assessed by
speciﬁc immunoenzymatic assays. Diﬀerence among groups were evaluated by one-way ANOVA. P values were adjusted with Sidak’s
multiple comparison test: ∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001 between the indicated subgroups.
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reach peripheral compartments even years before the onset
of clinical symptoms. Herein, a validated animal model of
AD, i.e., SAMP8, and its control strain SAMR1 were used
to quantify the accumulation of Aβ, tau, α-syn in brain tis-
sues and RBCs and to compare them at diﬀerent stages of
progress of the disease.
Behavioural tests showed that SAMP8 mice develop an
age-dependent deﬁcit in spatial learning and memory perfor-
mance, as compared with control SAMR1 mice, endorsing
the validity of this animal model.
Consistent with previous data [1], Aβ was found to accu-
mulate in the brain of AD animals. Similarly, Aβ levels were
augmented in RBCs along with AD progression. This obser-
vation is of interest since Aβ levels in RBCs have been shown
to increase with ageing in humans and to decrease upon pro-
viding an antioxidant supplement [15]. A noteworthy aspect
we observed is a slower Aβ accumulation kinetics in RBCs
compared to that detected in the brain. In this respect, Aβ
increase in the brain and the onset of NDs have been linked
to blood-derived Aβ, which can enter the brain [47], even
preceding the neuronal and glial pathological alterations of
AD brains [48]. Nevertheless, this “peripheral sink hypothe-
sis” is still a bone of contention because inhibiting the Aβ-
producing enzyme in the periphery does not alter Aβ accu-
mulation in the CNS [49].
Similarly to what was observed for Aβ, tau and its phos-
phorylated form accumulated in the brain with ageing and/or
AD progression in the SAMmodel, as previously reported by
others [50, 51]. In particular, our data are consistent with evi-
dences that tau hyperphosphorylation is an integral part of
ageing and represents an early event in AD animal models
[30, 52]. A similar, albeit quite slower, accumulation kinetics
of tau and p-tau was found in the RBCs of SAMs, suggesting
this protein as a valuable RBC marker reﬂecting brain neuro-
pathology. Consistent with this hypothesis, signiﬁcantly ele-
vated concentrations of p-tau have been shown in the RBCs
of PD patients [11].
Overall, our data allow hypothesising that the increase in
the levels of Aβ, tau, and p-tau in the brain is due to an
enhanced production in neurons associated with the progres-
sion of AD. In this respect, the increase of the same proteins
in RBCs might result from an alteration of the blood-brain
barrier (BBB), leading to the subsequent leakage of proteins
from the brain to the blood. Therefore, further investigations
are needed to elucidate the degree of production of these pro-
teins in blood cells and the eﬃciency of proteasome systems
deputed to the degradation of misfolded proteins.
Altered levels of α-syn, a protein commonly associated
with PD, have recently been detected in the brain and CSF
of AD patients [53]. In the present study, α-syn levels in
the brain were found to be higher than those of age-
matched controls in the early analysed phase of AD progres-
sion, consistent with the increase in the expression of α-syn
found in 5-month SAMP8 [52]. Nevertheless, total α-syn
was found to decrease with AD progression and compara-
tively with controls when 8-month-old mice were examined.
The latter results are consistent with several ﬁndings report-
ing a signiﬁcant decrease in the total concentration of brain
α-syn in PD [54] and PD with dementia [55]. This partial
controversy in α-syn levels in the early phase of AD suggests
that SAMP8 does not fully reﬂect the human brain pathology
associated with α-syn. Of note, a diﬀerent trend was found
for α-syn in RBCs: indeed, RBCs from SAMP8 showed signif-
icantly higher total α-syn concentrations than age-matched
controls. These results are at odds with the data obtained in
human RBCs from PD patients presenting lower levels than
HC [11, 20] and highlight the need for further investigations
to elucidate putative diﬀerences in posttranslational α-syn
modiﬁcations, degradation pathways, and passage through
the BBB [56, 57].
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Figure 8: Quantitative detection of IL-1β. IL-1β levels were assessed in brain (a) and RBC (b) tissues from control animals (SAMR1) and
SAMP8 mice at 6 and 8 months of age. Each column represents the mean ± S E M value (n = 8). Diﬀerences among groups were
evaluated by one-way ANOVA. P values were adjusted with Sidak’s multiple comparison test: ∗P < 0 05 and ∗∗P < 0 01 between the
indicated subgroups.
12 Oxidative Medicine and Cellular Longevity
In addition to homoaggregates, the presence of hetero-
complexes of α-syn (α-syn-tau and α-syn-Aβ) has been doc-
umented both in cellular models and patients’ brains [5, 8, 9,
11, 58]. On this basis, α-syn heterocomplexes were measured
for the ﬁrst time in this experimental model through “home-
made” immunoenzymatic assays. Interestingly, α-syn was
shown to form heterocomplexes with Aβ and tau both in
brain tissues and RBCs of SAM mice, similarly to previous
data reported in human samples [5, 11, 22].
Both α-syn-Aβ and α-syn-tau concentrations in SAM
brains followed the same accumulation kinetics shown for total
α-syn. Indeed, the initial increment was followed by a decre-
ment in the second phase of AD compared to controls and
AD progression. Interestingly, α-syn-Aβ and α-syn-tau levels
in RBCs displayed a similar trend, presenting a signiﬁcant
increase in AD mice compared to controls and along with AD
progression. As observed for brain samples, α-syn heterocom-
plexes showed the same temporal kinetics of accumulation of
total α-syn in RBCs, too. Consistent with these data, α-syn-Aβ
concentrations in human RBCs were elevated in PD patients
and correlated with the progress of the disease [11]. Surpris-
ingly, our recent ﬁndings have probed a signiﬁcant decrease of
α-syn heterocomplexes in RBCs from AD patients [10]. These
ﬁndings point out the need for further investigations in relation
to the speciﬁc neurodegenerative disease and the ﬂuid compart-
ment in which these proteins are analysed.
With these data at our disposal, the accumulation of α-
syn and its heterocomplexes in RBCs does not seem to reﬂect
the brain trend. The discrepancy could be ascribed to the
traﬃcking across the BBB or to the diﬃculty of measuring
appropriately the α-syn oligomeric form [5].
In the present study, the possible relationship between AD
progression and inﬂammation was investigated by assessing
IL-1β levels, as one of the most important inﬂammatory medi-
ators, both in brain tissues and RBCs from SAMP8 and
SAMR1. In this sense, it has to be underlined that peripheral
and central cytokines are released upon inﬂammation [59]
and not strictly related to AD. Nevertheless, IL-1β has been
demonstrated to be signiﬁcantly higher in AD with respect to
controls in both humans and animals [27–29] and can be con-
sidered as a good marker of inﬂammation in an animal model
of this disease. In our hands, brain IL-1β levels increased in
an AD animal model at 8 months and in age-matched control,
as previously reported by others in the hippocampus [26]. Inter-
estingly, IL-1β concentrations were higher in RBCs than in the
brain. However, not surprisingly, RBCs have been identiﬁed
recently as a reservoir for cytokines, with a median concentra-
tion 12-fold higher than plasma [18]. RBC IL-1β levels were sig-
niﬁcantly elevated in the pathological animals, consistent with
the greater level of oxidative stress found in RBCs from SAMP8
[60]. These changes were particularly evident at 6 months, sug-
gesting that the cytokine accumulation in RBCs seems to follow
a faster kinetics compared to the cerebral cortex, and thus it
could represent an early diagnostic for its early stage. In this
respect, recent ﬁndings have highlighted a close link between
peripheral inﬂammation and accumulation of misfolded pro-
teins [11, 61]. For instance, inﬂammation has been shown to
augment Aβ levels through an increased production in the
brain, an increased inﬂux, and a decreased eﬄux, due to alter-
ations of the BBB [62]. Recently, peripheral inﬂammation has
been shown tomodulate the amyloid phenotype inmice by reg-
ulating blood-derived and local brain inﬂammatory cell popula-
tions involved in Aβ clearance [63]. On the other side, in animal
models, in AD and in aged brains, accumulation of Aβ seems to
trigger inﬂammatory responses with an enhanced production
of inﬂammatory factors, which have been localised in brain pla-
ques [64]. Besides the inﬂammasome pathway, amyloid ﬁbrils
have been proven to induce the secretion of proinﬂammatory
cytokines through the activation of the Toll-like receptor 2
[65]. Future studies will investigate the involvement of this
innate immune receptor in immune responses associated to
amyloidosis in an AD animal model. Among the limitations
of our study, it should be underlined that the available immu-
noenzymatic assays cannot distinguish the oligomeric ormono-
meric nature of ND-related proteins, both in brain tissues and
blood. Further studies will conﬁrm the multiaggregation status
of these proteins.
In conclusion, we proved in the present study that Aβ, tau,
and p-tau kinetics of accumulation in RBCs from SAMP8
followed similar patterns to those in the brain, suggesting these
proteins as putative peripheral biomarkers of AD. Future stud-
ies will be needed to conﬁrm our preliminary data.
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